{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"634.096","value":"1022.35"},{"groupId":"OG001","spread":"697.078","value":"930.18"},{"groupId":"OG002","spread":"1220.166","value":"2092.25"},{"groupId":"OG003","spread":"1329.794","value":"2034.42"},{"groupId":"OG004","spread":"1191.873","value":"1469.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.501","value":"47.67"},{"groupId":"OG001","spread":"57.388","value":"-65.24"},{"groupId":"OG002","spread":"523.789","value":"203.25"},{"groupId":"OG003","spread":"567.584","value":"-98.83"},{"groupId":"OG004","spread":"24.042","value":"-110.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"161.220","value":"292.00"},{"groupId":"OG001","spread":"31.109","value":"17.30"},{"groupId":"OG002","spread":"140.950","value":"67.50"},{"groupId":"OG003","spread":"98.223","value":"-109.77"},{"groupId":"OG004","spread":"56.569","value":"-96.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"245.814","value":"101.65"},{"groupId":"OG001","spread":"76.619","value":"70.03"},{"groupId":"OG002","spread":"453.658","value":"154.50"},{"groupId":"OG003","spread":"364.312","value":"-92.87"},{"groupId":"OG004","spread":"200.818","value":"135.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"709.602","value":"307.58"},{"groupId":"OG001","spread":"46.054","value":"-6.70"},{"groupId":"OG002","spread":"833.804","value":"532.00"},{"groupId":"OG003","spread":"314.682","value":"353.77"},{"groupId":"OG004","spread":"536.324","value":"-383.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"689.052","value":"409.83"},{"groupId":"OG001","spread":"48.295","value":"-21.15"},{"groupId":"OG002","spread":"649.850","value":"875.00"},{"groupId":"OG003","spread":"275.281","value":"619.00"},{"groupId":"OG004","spread":"82.731","value":"-153.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"680.559","value":"349.00"},{"comment":"Standard deviation was not calculated for a single participant.","groupId":"OG001","spread":"NA","value":"172.00"},{"groupId":"OG002","spread":"394.335","value":"574.00"},{"groupId":"OG003","spread":"502.323","value":"516.10"},{"groupId":"OG004","spread":"211.425","value":"-106.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"614.180","value":"297.67"},{"groupId":"OG001","spread":"152.028","value":"488.50"},{"groupId":"OG002","spread":"362.417","value":"347.33"},{"groupId":"OG003","spread":"264.246","value":"442.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB at Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"658.316","value":"365.50"},{"comment":"Standard deviation was not calculated for a single participant.","groupId":"OG001","spread":"NA","value":"971.00"},{"groupId":"OG002","spread":"222.172","value":"315.33"},{"groupId":"OG003","spread":"64.559","value":"507.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"CFB at Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"Change from Baseline (CFB) was calculated as the post-Baseline value minus the Baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"Full Analysis Set-MDS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline; Cycle 1 Day 8; Cycle 1 Day 15; Cycles 2, 3, 4, 5, 6, and 7 Day 1","title":"Change From Baseline in Ferritin","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter"}